You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Johnson and Johnson
Colorcon
Medtronic
Dow

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SELEXIPAG

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Selexipag

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01106014 Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Completed Actelion Phase 3 2009-12-01 The AC-065A302 GRIPHON study is an event-driven Phase 3 study to demonstrate the effect of ACT-293987 on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
NCT01112306 ACT-293987 in Pulmonary Arterial Hypertension Active, not recruiting Actelion Phase 3 2009-12-01 Long-term, single-arm, multicenter, open-label extension, Phase 3 study, to evaluate the safety and tolerability of ACT-293987 in patients with PAH who participated in the double-blind study AC-065A302 (GRIPHON)
NCT02206204 Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects Completed Actelion Phase 1 2012-06-01 This is a single-center, double-blind, randomized, placebo- and positive-controlled, double-dummy, parallel-group, multiple-dose, up-titration study with a nested cross-over comparison between moxifloxacin and placebo in healthy male and female subjects. The primary objective is to demonstrate that selexipag and its metabolite ACT-333679 do not have an effect on cardiac repolarization exceeding the threshold of regulatory concern, at two orally administered dose levels (800 and 1600 μg twice daily) in healthy male and female subjects. Moxifloxacin is included as a positive control.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Selexipag

Condition Name

Condition Name for Selexipag
Intervention Trials
Pulmonary Arterial Hypertension 8
Healthy Subjects 5
Raynaud's Phenomenon Secondary to Systemic Sclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Selexipag
Intervention Trials
Hypertension 11
Familial Primary Pulmonary Hypertension 8
Hypertension, Pulmonary 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Selexipag

Trials by Country

Trials by Country for Selexipag
Location Trials
United States 71
Canada 15
Australia 13
Germany 9
France 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Selexipag
Location Trials
Michigan 5
California 5
Texas 4
Pennsylvania 4
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Selexipag

Clinical Trial Phase

Clinical Trial Phase for Selexipag
Clinical Trial Phase Trials
Phase 4 2
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Selexipag
Clinical Trial Phase Trials
Completed 9
Not yet recruiting 6
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Selexipag

Sponsor Name

Sponsor Name for Selexipag
Sponsor Trials
Actelion 19
Janssen Research & Development, LLC 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Selexipag
Sponsor Trials
Industry 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.